KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Total Liabilities (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Total Liabilities data on record, last reported at $778.7 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 3.3% year-over-year to $778.7 million; the TTM value through Dec 2025 reached $778.7 million, up 3.3%, while the annual FY2025 figure was $778.7 million, 3.3% up from the prior year.
  • Total Liabilities reached $778.7 million in Q4 2025 per PACB's latest filing, up from $767.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.2 billion in Q4 2021 and bottomed at $753.9 million in Q4 2024.
  • Average Total Liabilities over 5 years is $1.0 billion, with a median of $1.0 billion recorded in 2023.
  • Peak YoY movement for Total Liabilities: surged 1449.24% in 2021, then decreased 27.84% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $1.2 billion in 2021, then decreased by 0.97% to $1.2 billion in 2022, then decreased by 13.24% to $1.0 billion in 2023, then fell by 27.84% to $753.9 million in 2024, then increased by 3.3% to $778.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $778.7 million in Q4 2025, $767.1 million in Q3 2025, and $764.0 million in Q2 2025.